

CSD/BSE&NSE/BM/2024-25

November 12, 2024

To
The Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

Scrip Code: 543064

Scrip Symbol: SUVENPHAR

Dear Sir/Madam,

Sub: Outcome of the Board Meeting

.....

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015 (“SEBI Listing Regulations”), we wish to inform you that the Board of Directors of the Company (“Board”) at its meeting held today, i.e., on November 12, 2024, has, *inter alia*, approved the following matters:

1. Approved the Un-Audited Standalone and Consolidated Financial Results prepared under Ind AS for the quarter and half year ended September 30, 2024, pursuant to Regulation 33 of the SEBI Listing Regulations. In this connection, we annexed herewith the following documents:
 - a) Un-audited Standalone and Consolidated Financial Results under Ind AS for quarter and half year ended September 30, 2024;
 - b) Limited Review Reports on the above financial results;
 - c) Press Release on the financial results; and
 - d) Investors’ Presentation.
2. Approved the appointment of Mr. Jai Shankar Krishnan (DIN: 01519264), as an additional and Independent Director of the Company, as recommended by the Nomination and Remuneration Committee, for a period of five years with effect from November 12, 2024, subject to approval of the shareholders through postal ballot process.

Mr. Jai Shankar Krishnan is not related to any of the Directors or Key Managerial Personnel of the Company and is not debarred from holding the office of Director by virtue of any SEBI order or any other such authority.

The relevant details as required under the SEBI Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, including profile of Mr. Jai Shankar Krishnan are annexed herewith as ‘Annexure - A’.

3. Approved the appointment of Mr. Vinod Padikkal (DIN: 07765484), as an additional Non-Executive and Non-Independent Director of the Company, as recommended by the Nomination and Remuneration Committee, with effect from November 12, 2024, subject to approval of the shareholders through postal ballot process.

Suven Pharmaceuticals Limited

Registered Office: # 215 Atrium, C Wing, 8th Floor,
819-821, Andheri Kurla Road, Chakala, Andheri East,
Chakala Midc, Mumbai- 400093, Maharashtra, India
Tel: 91 22 61539999

Corporate Office: # 202, A-Wing, Galaxy Towers,
Plot No.1, Hyderabad Knowledge City, TSIC,
Raidurg, Hyderabad - 500081 Telangana, India
Tel: 91 40 2354 9414 / 3311

Email: info@suvенpharm.com | Website: www.suvenpharm.com | CIN: L24299MH2018PLC422236

Mr. Vinod Padikkal is not related to any of the Directors or Key Managerial Personnel of the Company and is not debarred from holding the office of Director by virtue of any SEBI order or any other such authority.

The relevant details as required under the SEBI Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, including profile of Mr. Vinod Padikkal are annexed herewith as 'Annexure - B'.

We request you to take these documents in your records. The Board Meeting commenced at 04.40 PM IST concluded at 06.08 P.M. IST

This is for your information and record.

Yours faithfully,
For **Suven Pharmaceuticals Limited**

Kundan Kumar Jha
*Company Secretary, Compliance Officer and
Head-Legal*

Encl: as above

Suven Pharmaceuticals Limited

Registered Office: # 215 Atrium, C Wing, 8th Floor,
819-821, Andheri Kurla Road, Chakala, Andheri East,
Chakala Midc, Mumbai- 400093, Maharashtra, India
Tel: 91 22 61539999

Corporate Office: # 202, A-Wing, Galaxy Towers,
Plot No.1, Hyderabad Knowledge City, TSIC,
Raidurg, Hyderabad - 500081 Telangana, India
Tel: 91 40 2354 9414 / 3311

Email: info@suvenpharm.com | Website: www.suvenpharm.com | CIN: L24299MH2018PLC422236

Disclosure of information pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023

Annexure - 2A

(1)	Name of Director	Mr. Jai Shankar Krishnan
(2)	Reason for change viz. appointment, resignation, removal, death or otherwise	Appointment as an Additional Director, in the category of an Independent Director
(3)	Date of appointment & Term of appointment	November 12, 2024 Appointment by the Board of Directors on November 12, 2024, as an Additional Director, in the category of an Independent Director, for a term of five consecutive years, with effect from November 12, 2024 to November 11, 2029. The said appointment is subject to approval of the shareholders of the Company through Postal Ballot process.
(4)	Brief profile (in case of appointment)	Brief profile is annexed herewith as Annexure -A1
(5)	Disclosure of relationships between directors (in case of appointment of a director)	Mr. Jai Shankar Krishnan is not related to any of the Directors or Key Managerial Personnel of the Company.
(6)	Information as required under Circular No. LIST/COMP/14/2018-19 and NSE/CML/2018/02 dated June 20, 2018 issued by the BSE and NSE, respectively.	Mr. Jai Shankar Krishnan is not debarred from holding the office of Director by virtue of any SEBI order or any other such authority.

Suven Pharmaceuticals Limited

Registered Office: # 215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala, Andheri East, Chakala Midc, Mumbai- 400093, Maharashtra, India
Tel: 91 22 61539999

Corporate Office: # 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad Knowledge City, TSIC, Raidurg, Hyderabad - 500081 Telangana, India
Tel: 91 40 2354 9414 / 3311

Email: info@suvenpharm.com | Website: www.suvenpharm.com | CIN: L24299MH2018PLC422236

Annexure – A1

Profile of Mr. Jai Shankar Krishnan



Mr. Jai Shankar Krishnan has since September 2019, been spearheading strong growth for Danaher Corporation from High Growth Markets. The High Growth Market geographies include India, Japan, Korea, Eastern Europe, Latin America, Middle East, Africa, Turkey, Southeast Asia, Australia, and New Zealand. In 2017, Mr. Krishnan expanded his leadership role at Danaher Corporation to include Southeast Asia. He joined Danaher Corporation as President and CEO for India in 2008. Before joining Danaher, Mr. Krishnan has worked with PerkinElmer Life and Analytical Sciences as President – India; Novartis Healthcare Pvt Ltd. as Head Global Services – India, GlaxoSmithKline Pharmaceuticals Ltd. as Business Unit Head. He started his career with Hindustan Unilever.

Mr. Krishnan is a Harvard Business School Alumni; Associate Certified Coach from International Coaching Federation; Global Lean Manufacturing certification and Six Sigma Master Blackbelts; META Leadership Program from Harvard T. H. Chan School of Public Health & Harvard Kennedy School of Govt. He is also MBA from Birla Institute of Technology.

Suven Pharmaceuticals Limited

Registered Office: # 215 Atrium, C Wing, 8th Floor,
819-821, Andheri Kurla Road, Chakala, Andheri East,
Chakala Midc, Mumbai- 400093, Maharashtra, India
Tel: 91 22 61539999

Corporate Office: # 202, A-Wing, Galaxy Towers,
Plot No.1, Hyderabad Knowledge City, TSIC,
Raidurg, Hyderabad - 500081 Telangana, India
Tel: 91 40 2354 9414 / 3311

Email: info@suvenpharm.com | Website: www.suvenpharm.com | CIN: L24299MH2018PLC422236

Disclosure of information pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023

Annexure - B

(1)	Name of Director	Mr. Vinod Padikkal
(2)	Reason for change viz. appointment, resignation, removal, death or otherwise	Appointment as an Additional Director, in the category of Non-Executive and Non-Independent Director
(3)	Date of appointment & Term of appointment	November 12, 2024 Appointment by the Board of Directors on November 12, 2024, as an Additional Director, in the category of Non-Executive and Non-Independent Director, with effect from November 12, 2024, liable to retire by rotation. The said appointment is subject to approval of the shareholders of the Company through Postal Ballot process.
(4)	Brief profile (in case of appointment)	Brief profile is annexed herewith as Annexure B-1
(5)	Disclosure of relationships between directors (in case of appointment of a director)	Mr. Vinod Padikkal is not related to any of the Directors or Key Managerial Personnel of the Company.
(6)	Information as required under Circular No. LIST/COMP/14/2018-19 and NSE/CML/2018/02 dated June 20, 2018 issued by the BSE and NSE, respectively.	Mr. Vinod Padikkal is not debarred from holding the office of Director by virtue of any SEBI order or any other such authority.

Suven Pharmaceuticals Limited

Registered Office: # 215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala, Andheri East, Chakala Midc, Mumbai- 400093, Maharashtra, India
Tel: 91 22 61539999

Corporate Office: # 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad Knowledge City, TSIC, Raidurg, Hyderabad - 500081 Telangana, India
Tel: 91 40 2354 9414 / 3311

Email: info@suvenpharm.com | Website: www.suvenpharm.com | CIN: L24299MH2018PLC422236

Annexure – B-1

Profile of Mr. Vinod Padikkal



Mr. Vinod Padikkal is a Senior Portfolio Manager within ADIA's Private Equities Department covering the India and Southeast Asia region, where he has managed and advised several portfolio investments in these regions as a part of his role.

Prior to joining ADIA in 2021, Mr. Padikkal has experience as a director at Advent International in India, and at Bain Capital and Bain & Co. in India, where he also successfully helped advise portfolio companies in their operations and management.

Mr. Padikkal holds a B. Tech in computer science and engineering from Cochin University of Science and Technology, and holds an MBA from IIM Ahmedabad. He has experience in holding directorship positions on several boards including ASK Investment Managers, Manjushree Technopack and Enamor.

Suven Pharmaceuticals Limited

Registered Office: # 215 Atrium, C Wing, 8th Floor,
819-821, Andheri Kurla Road, Chakala, Andheri East,
Chakala Midc, Mumbai- 400093, Maharashtra, India
Tel: 91 22 61539999

Corporate Office: # 202, A-Wing, Galaxy Towers,
Plot No.1, Hyderabad Knowledge City, TSIC,
Raidurg, Hyderabad - 500081 Telangana, India
Tel: 91 40 2354 9414 / 3311

Email: info@suvenpharm.com | Website: www.suvenpharm.com | CIN: L24299MH2018PLC422236



SUVEN PHARMACEUTICALS LIMITED

Regd. Off: 215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala, Andheri East,
Chakala Midc, Mumbai, Mumbai, Maharashtra, India, 400093

STATEMENT OF UNAUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 SEPTEMBER 2024

Rs. in Crores

PART - I		STANDALONE					
		Quarter ended			Half year ended		For the year ended
		30-Sep-24	30-Jun-24	30-Sep-23	30-Sep-24	30-Sep-23	31-Mar-24
Sl. No.	PARTICULARS	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Income						
	Revenue from operations	236.06	222.09	224.62	458.15	568.65	1,024.99
	Other income	13.43	17.95	14.20	31.38	24.26	55.09
	Total income	249.49	240.04	238.82	489.53	592.91	1,080.08
2	Expenses						
	a) Cost of materials consumed	39.17	34.73	46.95	73.90	124.57	248.38
	b) Changes in inventories of finished goods and work-in-progress	6.84	21.97	8.97	28.81	30.47	53.88
	c) Employee benefits expense	44.25	42.87	28.61	87.12	56.82	126.88
	d) Finance costs	1.47	1.60	1.14	3.07	2.99	7.43
	e) Depreciation and amortisation expense	12.29	12.00	10.53	24.29	21.75	48.79
	f) Other expenses	44.79	39.48	42.05	84.27	88.08	185.95
	Total expenses	148.81	152.65	138.25	301.46	324.68	671.31
3	Profit before tax (1-2)	100.68	87.39	100.57	188.07	268.23	408.77
4	Tax expenses						
	a) Current tax	27.91	20.02	24.29	47.93	65.60	98.14
	b) Current tax - earlier years	-	-	-	-	-	(0.78)
	c) Deferred tax	(3.56)	2.30	1.55	(1.26)	3.59	6.59
5	Net Profit for the period/year(3-4)	76.33	65.07	74.73	141.40	199.04	304.82
6	Other comprehensive income/ (loss)						
6.a	(i) Items that will not be reclassified to profit or loss	(0.10)	-	-	(0.10)	0.01	(0.39)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	0.03	-	-	0.03	(0.00)	0.10
6.b	(i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total other comprehensive income/(loss)	(0.07)	-	-	(0.07)	0.01	(0.29)
7	Total comprehensive income for the period/year	76.26	65.07	74.73	141.33	199.05	304.53
8	Paid-up equity share capital	25.46	25.46	25.46	25.46	25.46	25.46
	Face Value of the Share	Re.1.00	Re.1.00	Re.1.00	Re.1.00	Re.1.00	Re.1.00
9	Other equity						2,030.44
10	Earning Per Share (EPS)-Face value of Rs. 1/- each						
	a) Basic	3.00	2.56	2.94	5.55	7.82	11.97
	b) Diluted	2.98	2.56	2.94	5.54	7.82	11.97
		(not annualised)	(annualised)				

Note: Amounts less than Rs. 50,000 is presented as Rs. 0.00 crores



daljy.

PART - II		CONSOLIDATED					
Sl. No.	PARTICULARS	Quarter ended			Half year ended		For the year ended
		30-Sep-24	30-Jun-24	30-Sep-23	30-Sep-24	30-Sep-23	31-Mar-24
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Income						
	Revenue from operations	257.72	230.69	231.05	488.41	578.60	1,051.35
	Other income	14.12	18.16	19.84	32.28	30.51	61.91
	Total income	271.84	248.85	250.89	520.69	609.11	1,113.26
2	Expenses						
	a) Cost of materials consumed	47.08	38.30	51.16	85.38	130.93	265.88
	b) Changes in inventories of finished goods and work-in-progress	4.98	25.30	6.45	30.28	27.95	49.15
	c) Employee benefits expense	51.87	45.32	30.68	97.19	61.36	135.92
	d) Finance costs	1.67	1.60	1.14	3.27	2.99	7.45
	e) Depreciation and amortisation expense	16.96	13.40	11.95	30.36	24.56	54.60
	f) Other expenses	49.78	41.84	44.12	91.62	91.98	194.59
	Total expenses	172.34	165.76	145.50	338.10	339.77	707.59
3	Profit before tax (1-2)	99.50	83.09	105.39	182.59	269.34	405.67
4	Tax expenses						
	a) Current tax	27.91	20.02	24.29	47.93	65.60	99.58
	b) Current tax - earlier years	-	-	-	-	-	(0.78)
	c) Deferred tax	(10.39)	2.30	1.55	(8.09)	3.59	6.59
5	Net Profit for the period/year (3-4)	81.98	60.77	79.55	142.75	200.15	300.28
6	Net Profit for the period/year attributable to						
	a) Shareholders of the company	82.21	60.77	79.55	142.98	200.15	300.28
	b) Non-controlling interest	(0.23)	-	-	(0.23)	-	-
7	Other comprehensive income						
7.a	(i) Items that will not be reclassified to profit or loss	(0.10)	-	-	(0.10)	0.01	0.11
	(ii) Income tax relating to items that will not be reclassified to profit or loss	0.03	-	-	0.03	(0.00)	0.10
7.b	(i) Items that will be reclassified to profit or loss	0.01	0.59	-	0.60	-	13.00
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total other comprehensive income	(0.06)	0.59	-	0.53	0.01	13.21
8	Total comprehensive income for the period/year (5+6)	81.92	61.36	79.55	143.28	200.16	313.49
9	Total comprehensive income for the period/year attributable to						
	a) Shareholders of the company	82.15	61.36	79.55	143.51	200.16	313.49
	b) Non-controlling interest	(0.23)	-	-	(0.23)	-	-
10	Paid-up equity share capital	25.46	25.46	25.46	25.46	25.46	25.46
	Face Value of the Share	Re. 1.00					
11	Other equity						2,025.21
12	Earning Per Share (EPS)- (Face value of Rs. 1/- each)						
	a) Basic -	3.23	2.39	3.12	5.62	7.86	11.80
	b) Diluted	3.21	2.39	3.12	5.60	7.86	11.80
		(not annualised)	(annualised)				





SUVEN PHARMACEUTICALS LIMITED

Regd. Off: 215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurta Road, Chakala, Andheri East, Chakala Midc, Mumbai, Mumbai, Maharashtra, India, 400093

Statement of assets and liabilities

Rs. in Crores

Particulars	Standalone as at		Consolidated as at	
	30-Sep-24 Unaudited	31-Mar-24 Audited	30-Sep-24 Unaudited	31-Mar-24 Audited
A ASSETS				
1 Non-current assets				
(a) Property, plant and equipment	481.51	496.91	606.50	567.22
(b) Right of use of assets	29.64	25.07	45.44	40.58
(c) Capital work-in-progress	240.82	178.97	240.82	178.97
(d) Goodwill	-	-	213.76	60.25
(e) Other intangible assets	1.48	1.56	57.70	1.57
(f) Intangible assets under development	0.08	0.11	0.08	0.11
(g) Financial assets				
I. Investments	575.21	317.21	132.14	130.58
II. Loans	0.01	0.01	0.01	0.01
III. Other financial assets	8.44	9.35	9.88	9.37
(h) Income tax asset, (net)	10.85	10.85	13.57	9.99
(i) Deferred tax asset, (net)	-	-	7.38	0.81
(j) Other non-current assets	10.46	1.97	10.63	2.24
Total non-current assets	1,358.50	1,042.01	1,337.91	1,001.70
2 Current assets				
(a) Inventories	194.86	220.07	215.48	231.20
(b) Financial assets				
I. Investments	614.75	767.45	619.06	773.90
II. Trade receivables	164.35	126.97	183.95	133.66
III. Cash and cash equivalents	5.40	18.31	36.82	47.23
IV. Bank balances other than (III) above	5.33	3.27	5.33	3.27
V. Loans	1.70	0.83	1.70	0.83
VI. Other financial assets	0.27	0.43	11.77	0.43
(c) Other current assets	53.25	61.37	58.86	62.69
(d) Assets of disposal group classified as held for sale	-	-	34.68	-
Total current assets	1,039.91	1,198.70	1,167.65	1,253.21
TOTAL - ASSETS	2,398.41	2,240.71	2,505.56	2,254.91
B EQUITY AND LIABILITIES				
1 Equity				
(a) Equity share capital	25.46	25.46	25.46	25.46
(b) Other equity	2,180.63	2,030.44	1,952.88	2,025.21
Equity attributable to owners	2,206.09	2,055.90	1,978.34	2,050.67
Non-controlling interest	-	-	50.08	-
Total equity	2,206.09	2,055.90	2,028.42	2,050.67
2 LIABILITIES				
(a) Financial liabilities				
I. Borrowings	-	-	7.14	-
II. Lease liabilities	22.96	21.24	23.52	21.24
(b) Provisions	0.15	0.72	2.31	0.73
(c) Deferred tax liabilities, (net)	46.86	48.14	85.93	65.60
(d) Other financial liabilities	-	-	120.10	-
Total non-current liabilities	69.97	70.10	239.00	87.57
Current liabilities				
(a) Financial liabilities				
I. Borrowings	-	38.58	1.93	38.58
II. Lease liabilities	6.68	5.19	6.87	5.19
III. Trade payables				
a) Total outstanding dues of micro enterprises and small enterprises	9.88	17.05	10.12	17.07
b) Total outstanding dues of creditors other than micro enterprises and small enterprises	50.56	24.20	55.16	25.28
IV. Other financial liabilities	18.98	8.75	125.21	8.84
(b) Other current liabilities	8.45	7.02	8.90	7.20
(c) Provisions	14.97	13.92	17.13	14.51
(d) Income tax liabilities, (net)	12.83	-	12.82	-
Total liabilities	122.35	114.71	238.14	116.67
Total liabilities	192.32	184.81	477.14	204.24
TOTAL - EQUITY AND LIABILITIES	2,398.41	2,240.71	2,505.56	2,254.91





SUVEN PHARMACEUTICALS LIMITED

Regd. Off: 215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala, Andheri East,
Chakala Midc, Mumbai, Mumbai, Maharashtra, India, 400093

Disclosure of Standalone Statement of Cash Flows as per Regulation 33 of the SEBI(Listing Obligations and Disclosure Requirements) Regulations, 2015 for the half year ended September 30, 2024

Rs. in Crores

Particulars	For half year ended 30-Sep-2024	For half year ended 30-Sep-2023
A. Cash flow from operating activities		
Profit before tax	188.07	268.23
Adjustments :		
Depreciation and amortisation expense	24.29	21.30
Finance costs	2.81	1.65
Loss on disposal of property, plant and equipment	0.05	0.03
Share based payment expense	8.86	-
Interest income	(0.33)	(1.06)
Unrealised foreign exchange fluctuations, (net)	(3.77)	0.69
Net fair value gain on financial instruments	(0.05)	-
Fair value gain on current investment carried at fair value through profit or loss	(20.92)	(15.08)
Net gain on sale of current investment carried at fair value through profit or loss	(5.47)	(2.20)
Balances no longer required written back	(0.26)	-
Operating profit before working capital changes	193.28	273.56
Adjustments for working capital		
Decrease in inventories	25.21	47.45
(Increase)/decrease in trade and other receivables	(26.57)	25.92
Increase/(decrease) in trade payables and other liabilities	20.28	(24.81)
Cash generated from operations	212.20	322.12
Income taxes paid (net of refunds)	(35.10)	(65.47)
Net cash flows generated from operating activities (A)	177.10	256.65
B. Cash flow from investing activities		
Purchase of property, plant and equipment (refer note (ii) below)	(67.02)	(24.76)
Investment in subsidiaries (Refer Note 4)	(258.00)	-
Sale/(purchase) of current investments, (net)	179.09	(225.81)
Interest received	0.50	1.06
Change in other bank balance and cash not available for immediate use	-	(0.81)
Net cash flow used in investing activities (B)	(145.43)	(250.32)
C. Cash flows from financing activities		
Repayment of short-term borrowings	(38.58)	(4.57)
Repayment of long-term borrowings	-	(15.90)
Repayment of lease liabilities		
- Principal paid	(3.18)	(0.42)
- Interest paid	(1.35)	(0.06)
Finance costs paid	(1.47)	(1.65)
Net cash flow used in financing activities (C)	(44.58)	(22.60)
Net decrease in cash and cash equivalents (A+B+C)	(12.91)	(16.27)
Cash and cash equivalents as at the beginning of the period	18.31	43.02
Cash and cash equivalents at the end of the period	5.40	26.75

Notes:

i. The above statement of cashflow has been prepared under the 'Indirect Method' as set out in Indian Accounting Standard (Ind AS) 7-Statement of Cash Flows.

ii. Purchase and sale of property, plant and equipment represents additions and deletions to property, plant and equipment and investment properties adjusted for movement of capital work-in-progress, capital advances, capital creditors during the period.



Disclosure of Consolidated Statement of Cash Flows as per Regulation 33 of the SEBI(Listing Obligations and Disclosure Requirements) Regulations, 2015 for the half year ended September 30, 2024

Rs. in Crores

Particulars	For half year ended 30-Sep-2024	For half year ended 30-Sep-2023
A. Cash flow from operating activities		
Profit before tax	182.59	269.34
Adjustments :		
Depreciation and amortisation expense	30.35	24.10
Finance costs	3.00	1.65
Loss on disposal of property, plant and equipment	0.05	0.03
Share based payment expense	8.86	-
Interest income	(0.63)	(6.35)
Unrealised foreign exchange fluctuations, (net)	(4.20)	0.69
Net fair value gain on financial instruments	(0.05)	-
Fair value gain on current investment carried at fair value through profit or loss	(21.03)	(15.08)
Net gain on sale of current investment carried at fair value through profit or loss	(5.47)	(2.20)
Balances no longer required written back	(0.26)	-
Operating profit before working capital changes	193.21	272.18
Adjustments for working capital		
Decrease in inventories	24.72	41.35
(Increase)/decrease in trade and other receivables	(25.71)	26.51
Increase/(decrease) in trade payables and other liabilities	22.83	(22.25)
Cash generated from operations	215.05	317.79
Income taxes paid (net of refunds)	(37.38)	(65.48)
Net cash flows generated from operating activities (A)	177.67	252.31
B. Cash flow from Investing activities		
Purchase of property, plant and equipment and intangible assets	(69.45)	(25.86)
Purchase consideration for acquisition of business (net of cash acquired of ₹1.44) (Refer note 4)	(256.56)	-
Sale/(purchase) of current investments, (net)	181.35	(217.35)
Interest received	0.85	7.11
Changes in other bank balance and fixed deposits	1.52	(0.83)
Net cash flow used in investing activities (B)	(142.29)	(236.93)
C. Cash flows from financing activities		
Repayment of short term borrowings	(39.48)	(15.90)
Repayment of long term borrowings	-	(4.57)
Repayment of lease liabilities		
- Principal paid	(3.31)	(0.42)
- Interest paid	(1.37)	(0.06)
Finance costs paid	(1.63)	(1.65)
Net cash flow used in financing activities (C)	(45.79)	(22.60)
Net decrease in cash and cash equivalents (A+B+C)	(10.41)	(7.22)
Cash and cash equivalents as at the beginning of the period	47.23	64.80
Cash and cash equivalents at the end of the period	36.82	57.58

Notes:

- The above statement of cashflow has been prepared under the 'Indirect Method' as set out in Indian Accounting Standard (Ind AS) 7-Statement of Cash Flows.
- Purchase and sale of property, plant and equipment represents additions and deletions to property, plant and equipment and investment properties adjusted for movement of capital work-in-progress, capital advances, capital creditors during the period.



Notes

- 1) The above results have been reviewed and recommended to the Board of Directors by the Audit Committee and subsequently approved by the Board of Directors at its meeting held on 12 November 2024. These results have been subjected to limited review by statutory auditors who have expressed an unmodified review conclusion. The financial results for the quarter ended 30 June 2024 and 30 September 2023, half year ended 30 September 2023 and year ended 31 March 2024 were reviewed/audited by Karvy & Co., Chartered Accountants (predecessor auditors).
- 2) The above financial results are prepared in accordance with the Indian Accounting Standard prescribed under section 133 of the Companies Act, 2013 and are in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).
- 3) The Company reportable activity falls under single operating segment i.e. Manufacturing (CRAMS) - Bulk Drugs & Intermediates & Services, hence segment reporting as per Ind AS 108 (Operating Segment) is not presented.
- 4) Pursuant to definitive agreements entered by the company with Sapala Organics Private Limited ("Sapala"), the company has acquired 51% of the share capital on a fully diluted basis (i.e., 67.5% of the present equity share capital) of Sapala on 12 July 2024 for a consideration of ₹258.00 crore and gained control of Sapala Organics Private Limited ("Sapala") as a subsidiary. As at 12 July 2024, the fair value of assets and liabilities acquired have been determined by the Group and accounted for in accordance with IND AS 103 - "Business Combination".
- The Company has obligation to acquire the non-controlling interest in 2 tranches, one based on achievement of business performance milestones and another one based on regulatory approval. The obligation has been accounted for as a liability in the consolidated financial results on the acquisition date at its fair value of ₹224.69 crore with a corresponding debit to other equity. Subsequent to initial recognition of the financial liability, the Company would recognise the changes in the carrying amount of the financial liability within the other equity.
- The fair value of assets and liabilities acquired have been provisionally determined by the Company and accounted for in accordance with IND AS 103 - "Business Combination". Financial results for the quarter and half year ended 30 September 2024, include the impact of the above transaction with effect from 12 July 2024 and are not comparable with previous corresponding periods.
- Total consideration has been allocated based on provisional purchase price allocation as under:

Particulars	Amount (₹ In crores)
Fair value of assets acquired including intangible assets	193.79
Fair value of liability assumed	(18.06)
Deferred tax liabilities on fair value of net assets acquired	(20.93)
Fair value of net assets acquired	154.80
Non-controlled interest in the acquired entity, based on their proportionate interest in the recognised amounts of identifiable net assets of Sapala	50.31
Total consideration paid	258.00
Goodwill	153.51

- 5) The Board of Directors had approved on 29 February 2024, the Scheme of Amalgamation of Cohance Life Sciences Limited (Transferor Company) into and with Suven Pharmaceuticals Limited ("The Company").
- Subsequent to the quarter and six months ended 30 September 2024, the NCLT vide its order pronounced on 22 October 2024 has directed the convening of the meetings of the shareholders of both the Transferor Company and the Transferee Company, for approving the Scheme of Amalgamation and dispensing with the meetings of secured and unsecured creditors and serve notices to the concerned regulatory authorities for seeking their representations, if any.
- Based on the NCLT directions, meetings of the equity shareholders of both the Transferor Company and the Transferee Company are scheduled to be held on 28 November 2024 to consider and if thought fit, approve the Scheme.
- The Scheme of Amalgamation remains subject to applicable approvals, including approvals from the Hon'ble NCLT, and such other approvals, permissions, and sanctions of regulatory and other authorities, as may be applicable.
- 6) The Board of directors of Suven Pharmaceuticals Limited ("Company" / "Transferee Company") has approved on 29 February 2024 the scheme of amalgamation of Casper Pharma Private Limited ("Transferor Company") (a wholly owned subsidiary of the Company) into and with the Company under the provisions of Sections 230 to 232 of the Companies Act, 2013 subject to receipt of applicable approval including approval from Hon'ble NCLT ("Scheme of Amalgamation").
- The Hon'ble NCLT, Mumbai Bench has passed an order dated 14 June 2024 dispensing with the meetings of equity shareholders, secured creditors and unsecured creditors of both the Transferor Company and the Transferee Company and directed, inter-alia the Transferor Company and the Transferee Company to serve notices through registered post on the concerned regulatory authorities for their objections, if any, to the sanctioning of the Scheme of Amalgamation.
- The Hon'ble NCLT, Mumbai vide its Order dated 24 October 2024 has, sanctioned the Scheme of Amalgamation. The Appointed Date of the Scheme would be the Effective Date as defined under the Scheme. Therefore, the Scheme will be effective on the opening hours of the first day of the month immediately succeeding the month in which the certified copy of the Order will be filed with the Registrar of Companies, Ministry of Corporate Affairs. Accordingly, the effect of the scheme shall be given in line with effective date (when the scheme shall be filed with ROC) and in the manner prescribed under the scheme.
- 7) The figures of the previous year/periods have been regrouped/recast to render them comparable with the figures of the current period.
- 8) The financial results for the quarter and six months ended 30 September 2023 and for the year ended 31 March 2024 were presented in INR Lakhs. With effect from quarter ended 30 June 2024, the Company has presented the financial results in INR crores. Consequently, the results for the comparative periods have also been presented in INR Crores.

Dr. V. PRASADA RAJU

Place : Hyderabad
Date : 12 November 2024



ms. dalgub
Managing Director
DIN: 07267366

Walker ChandioK & Co LLP

Walker ChandioK & Co LLP

L-41, Connaught Circus,
Outer Circle,
New Delhi - 110 001
India

T +91 11 4500 2219
F +91 11 4278 7071

Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Suven Pharmaceuticals Limited

1. We have reviewed the accompanying statement of standalone unaudited financial results ('the Statement') of Suven Pharmaceuticals Limited ('the Company') for the quarter ended 30 September 2024 and the year to date results for the period 01 April 2024 to 30 September 2024, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. The Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above and the consideration of the review reports of the branch auditors referred to in paragraph 5 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

Chartered Accountants

Offices in Ahmedabad, Bengaluru, Chandigarh, Chennai, Dehradun, Goa, Gurugram, Hyderabad, Indore, Kochi, Kolkata, Mumbai, New Delhi, Noida and Pune

Walker ChandioK & Co LLP is registered with limited liability with identification number AAC-2085 and has its registered office at L-41, Connaught Circus, Outer Circle, New Delhi, 110001, India.



Walker ChandioK & Co LLP

5. We did not review the interim financial information of one branch (Suven USA branch) included in the Statement, where such interim financial information reflects total assets of ₹1.08 crores at 30 September 2024, and total revenues of ₹Nil, total net loss after tax of ₹(4.69) crores and ₹(7.92) crores, total comprehensive loss of ₹(4.69) crores and ₹(7.92) crores, for the quarter and year-to-date period ended on 30 September 2024 for the quarter and year-to-date period ended on 30 September 2024, respectively, and cash flows(net) of ₹(0.49) crores for the six-month period ended 30 September 2024, as considered in the Statement. Such interim financial information has been reviewed by the branch auditors, whose reports have been furnished to us by the management, and our conclusion, in so far as it relates to the amounts and disclosures included in respect of this branch, is based solely on the review report of branch auditor.

Further, the above branch is located outside India whose interim financial information have been prepared in accordance with accounting principles generally accepted in their respective countries and which have been reviewed by branch auditor under Statement on Standards for Accounting and Review Services promulgated by the Accounting and Review Services Committee of the AICPA. The Company's management has converted the financial information of the branch from accounting principles generally accepted in its country to accounting principles generally accepted in India. We have reviewed these conversion adjustments made by the Company's management. Our conclusion, in so far as it relates to the balances and affairs of this branch is based on the review report of branch auditors and the conversion adjustments prepared by the management of the Company and reviewed by us.

Our conclusion on the Statement is not modified in respect of the above matter with respect to our reliance on the work done by and the reports of the branch auditors.

6. The review of standalone unaudited quarterly financial results for the period ended 30 June 2024, included in the Statement was carried out and reported by M/s. Karvy & Co., Chartered Accountants who has expressed unmodified conclusion vide their review report dated 9 August 2024, whose review report has been furnished to us and which has been relied upon by us for the purpose of our review of the Statement. Our conclusion is not modified in respect of this matter.
7. The review of standalone unaudited quarterly and year-to-date financial results for the period ended 30 September 2023 and audit of standalone financial results for the year ended 31 March 2024 included in the Statement was carried out and reported by M/s. Karvy & Co., Chartered Accountants who has expressed unmodified conclusion vide their review report dated 9 November 2023 and unmodified opinion vide their audit report dated 30 May 2024, respectively, whose reports have been furnished to us and which have been relied upon by us for the purpose of our review of the Statement. Our conclusion is not modified in respect of this matter.

For Walker ChandioK & Co LLP

Chartered Accountants

Firm Registration No: 001076N/N500013


Ashish Gupta
Partner
Membership No. 504662



UDIN: 24504662BKGEGZ2053

Place: New Delhi

Date: 12 November 2024

Walker Chandiook & Co LLP

Walker Chandiook & Co LLP

L-41, Connaught Circus,
Outer Circle,
New Delhi - 110 001
India

T +91 11 4500 2219
F +91 11 4278 7071

Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Suven Pharmaceuticals Limited

1. We have reviewed the accompanying statement of unaudited consolidated financial results ('the Statement') of Suven Pharmaceuticals Limited ('the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred to as 'the Group'), (refer Annexure 1 for the list of subsidiaries included in the Statement) for the quarter ended 30 September 2024 and the consolidated year to date results for the period 01 April 2024 to 30 September 2024 being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. This Statement, which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the SEBI Circular CIR/CFD/CMD1/44/2019 dated 29 March 2019 issued by the SEBI under Regulation 33 (8) of the Listing Regulation, to the extent applicable.



Chartered Accountants

Offices in Ahmedabad, Bengaluru, Chandigarh, Chennai, Dehradun, Goa, Gurugram, Hyderabad, Indore, Kochi, Kolkata, Mumbai, New Delhi, Noida and Pune

Walker Chandiook & Co LLP is registered with limited liability with identification number AAC-2085 and has its registered office at L-41, Connaught Circus, Outer Circle, New Delhi, 110001, India

Walker ChandioK &Co LLP

4. Based on our review conducted and procedures performed as stated in paragraph 3 above and upon consideration of the review reports of the branch auditors and other auditors referred to in paragraph 5 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. We did not review the interim financial statements/information of two subsidiaries included in the Statement and one branch (Suven USA branch) included in the unaudited interim standalone financial statements of the entities included in the Group, whose financial information reflects total assets of ₹ 276.24 crores as at 30 September 2024, and total revenues of ₹12.98 crores and ₹21.58 crores, total net profit/(loss) after tax of ₹1.68 crores and ₹(5.87) crores, total comprehensive profit/(loss) of ₹1.68 crores and ₹(5.87) crores, for the quarter and year-to-date period ended on 30 September 2024, respectively, and cash flows (net) of ₹(1.58) crores for the period ended 30 September 2024, as considered in the respective unaudited interim standalone financial statements/financial results of the entities included in the Group. These interim financial statements/information have been reviewed by other auditors and branch auditors whose review reports have been furnished to us by the management, and our conclusion in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and a branch is based solely on the review reports of such other auditors and branch auditors and the procedures performed by us as stated in paragraph 3 above.

Further, of these subsidiaries/branch, one subsidiary and one branch are located outside India, whose interim financial statements have been prepared in accordance with accounting principles generally accepted in their respective countries and which have been reviewed by other auditors and branch auditors under Statement on Standards for Accounting and Review Services promulgated by the Accounting and Review Services Committee of the AICPA. The Holding Company's management has converted the financial statements of such subsidiaries/branch from accounting principles generally accepted in their respective countries to accounting principles generally accepted in India. We have reviewed these conversion adjustments made by the Holding Company's management. Our conclusion, in so far as it relates to the balances and affairs of these subsidiaries/branch is based on the review report of other auditors and branch auditors and the conversion adjustments prepared by the management of the Holding Company and reviewed by us.

Our conclusion is not modified in respect of this/these matter(s) with respect to our reliance on the work done by and the reports of the other auditors.

6. The review of unaudited consolidated quarterly financial results for the period ended 30 June 2024, included in the Statement was carried out and reported by M/s. Karvy & Co., Chartered Accountants who have expressed unmodified vide their review report dated 9 August 2024, whose review report has been furnished to us by the management and which has been relied upon by us for the purpose of our review of the Statement. Our conclusion is not modified in respect of this matter.



Walker Chandiook & Co LLP

7. The review of unaudited consolidated quarterly and year-to-date financial results for the period ended 30 September 2023 and audit of consolidated financial results for the year ended 31 March 2024 included in the Statement was carried out and reported by M/s. Karvy & Co., Chartered Accountants who have expressed unmodified conclusion vide their review report dated 9 November 2023 and unmodified conclusion vide their audit report dated 30 May 2024, respectively, whose reports have been furnished to us and which have been relied upon by us for the purpose of our review of the Statement. Our conclusion is not modified in respect of this matter.

For Walker Chandiook & Co LLP
Chartered Accountants
Firm Registration No: 001076N/N500013


Ashish Gupta
Partner
Membership No. 504662



UDIN: 24504662BKGEGY4935

Place: New Delhi
Date: 12 November 2024



Suven Pharmaceuticals Announces Q2 and H1FY25 Results

Revenue grows by 12% in Q2 (YoY); Growth outlook maintained for FY25

Hyderabad, November 12, 2024

Suven Pharmaceuticals Ltd. (BSE: 530239, NSE: SUVENPHARM), a technology-led global Contract Development and Manufacturing Organization (CDMO), today announced its financial results for the second quarter and half year ended September 30, 2024.

The company reported progress in its strategic initiatives, including a strong pipeline in Phase III, an increase in Request for Quotations (RFQs), and conversion of Spec-Chem/Ag-Chem business to SBU, setting the stage for future growth. Revenue for the quarter stood at INR 258Cr., posting a growth of 12% YoY, and gross margins witnessed a 473 bps expansion driven primarily by business mix and the consolidation of the recently acquired oligonucleotide business. Adjusted EBITDA was Rs 112 Cr. with EBITDA margins at 43.3%.

Q2 and H1FY25 Financial Performance Highlights

- Q2 Pharma CDMO Performance: Pharma CDMO business has posted growth of 40% YoY in Q2 driven by BD efforts and backed by macro tailwinds, leading to a technology lead robust pipeline.
- H1 Performance:
 - Adjusted EBITDA & Adjusted PAT margins stood at 40.7% & 31.3% respectively.
 - Generated free cash flow of Rs 110 Cr. and maintained a cash & bank balance of Rs 656 Cr. Capex for H1FY25 was Rs 69.4 Cr.

Strategic and Operational Highlights:

- Phase III pipeline has expanded with the addition of one new Molecule
- One of our Phase III read-outs yielded positive results
- RFQ inflow grew by 2.2x vs in H1FY24, with a healthy mix of lateral projects, tech-led projects, and a broader set of customers.
- Continuing the efforts to convert SpecChem/AgChem business into a Strategic Business Unit; the Macro effect for AgChem has bottomed out, and we're seeing some early signs of recovery.
- We're looking to cross-sell and mine customer relationships to our oligonucleotides business.

Executive Commentary:

Mr. Vivek Sharma, Executive Chairman, said, *"There is a strong momentum favoring the CDMO sector, with India as the biggest beneficiary driven by efforts to diversify supply chains, along with supportive macroeconomic trends like the potential US Biosecure Act. Suven with its strong track record and extensive offerings, continues to be committed to offering a tech-led end-to-end CDMO platform to its customers."*

Dr. V. Prasada Raju, Managing Director, added, *"On the front end, we have continued our concerted BD efforts to serve both the large innovator customers as well as select Biotechs, and we can see the green shoots of our efforts in our robust RFQ pipeline. From a delivery perspective, we have focused on backward integration and expanding our capabilities across the value chain, so we are well prepared to take forward the opportunities we envisage across Small molecules, ADC platform, and oligonucleotides. Our outlook for the medium to long term remains healthy."*

Outlook:

Overall, there is no change in outlook. H1 has been in line with our estimates, while H2 will see better growth trajectory. We expect to grow on a full-year basis at a combined platform level with growth acceleration from FY26.

Suven Pharma has released its ESG report and uploaded the ESG profile on the company website. In H1, Suven Pharma achieved multiple certifications, including ISO22301 and ISO50001.

Earnings call details

Suven Pharmaceuticals Ltd will conduct a conference call to discuss its Q2 & H1FY25 results performance. The management team will be represented by Mr. Vivek Sharma (Executive Chairman), Dr. V Prasada Raju (Managing Director), Dr. Sudhir Kumar Singh (Chief Executive Officer), Mr. Himanshu Agarwal (Chief Financial Officer) and Cyndrella Carvalho (Head IR).

The conference call will be initiated with a brief discussion after which the floor will be opened for Q&As. The financial results will be announced earlier on May 30, 2024.

In order to pre-register - Copy this URL in your browser:

<https://services.choruscall.in/DiamondPassRegistration/register?confirmationNumber=1767413&linkSecurityString=bc11a94a4>

Details of the conference call are as follows:

Timing	: 6.30 pm IST on Tuesday, November 12, 2024
Conference dial-in Primary number	: +91 22 6280 1141 / +91 22 7115 8042
Hong Kong Local Access Number	: 800 964 448
Singapore Local Access Number	: 800 101 2045
UK Local Access Number	: 0 808 101 1573
USA Local Access Number	: 1 866 746 2133

-ENDS-

For more information, please visit www.suvenpharm.com OR contact:

Cyndrella Carvalho, Head – Investor Relations,

Suven Pharmaceutical Ltd

Tel: 040 2354 3311

Email: cyndrella.carvalho@suvenpharm.com

Gavin Desa / Rishab Barar

CDR India

Tel: +91 98206 37649/ +91 7770 35061

Email: gavin@cdr-india.com

rishab@cdr-india.com

Disclaimer: Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this presentation may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause these statements to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.



Suven Pharmaceuticals Ltd.

...Towards a Brighter Tomorrow

Investor Presentation – Q2 & H1FY25

Safe Harbour

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this presentation may be forward-looking statements that involve a number of risks and uncertainties. Although Seven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause these statements to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Seven may not undertake to update any forward-looking statements that may be made from time to time.



Table of Contents

Executive Summary	04
Q2 and H1FY25 Operating and Financial Performance	05
Combined Business: Proforma Metrics Q2 FY25	11
Combined Business: Key segment wise strategy	14
Strategic Blueprint	26
ESG Sapala Acquisition	28
Update on Amalgamation of Suven Pharmaceuticals with Cohance Lifesciences	30
Financial Performance Q2 and H1FY25	32
Annexure	42

Industry : Continue to witness secular macro tailwinds and positive customer sentiments driven by supply chain de-risking & potential US Biosecure Act

- Customer sentiment has been positive, as evidenced by several customer engagements and multiple new audits. This aligns well with our commitment to offering an advanced, combined platform that meets evolving customer needs.
- There are efforts by customers to diversify and stabilize supply chains, driven by macroeconomic trends including the potential US Biosecure Act.

Suven leadership update: Appointment of Vivek Sharma as the new Chairman and appointment of new Chief Commercial Officer (CCO)

- We have augmented our BD team efficiently in the US, EU and Asia (Japan) region to double down on our BD efforts amidst the secular macro tailwinds.
- Further capitalizing on our new BD team's expertise, apart from our continued focus on large innovator customers, we will also engage with Biotech firms selectively for oligonucleotides and ADCs along with the small molecule business.

Q2FY25 & H1FY25: Revenue growth of 12% YoY and 41% ex-Spec-chem in Q2 driven by growth in Pharma CDMO and Sapala's consolidation

- **Our strategic efforts** continues to yield **healthy inflow of RFQs** and visible with **progress in our pipeline**; H1 has received highest ever RFQs for Suven (2.2x Vs H1FY24) driven by BD efforts and backed by Macro tailwinds; RFQs more diverse including from newer customers – across regions and newer product categories; We're also witnessing a healthy share of laterals in the RFQs pipeline driven by supply de-risking efforts by customers.

Business Segment Updates:

- **Pharma CDMO:** 40% growth YoY in Q2FY25; Our Phase III pipeline has expanded by one new products; one phase III read-out has been positive.
- **Ag CDMO:** We have converted Ag Chem business into a dedicated strategic business unit. Macro effect has now bottomed out and we have started seeing green shoots from our concerted BD efforts in this segment which suggest early signs of recovery and visibility on the business in CY25
- **Oligonucleotides:** Sapala business has been consolidated from 11th July onwards. We have received the positive news that our pipeline product has received orphan drug status. Investments in cGMP facility are underway as planned.
- **Cohance:** As per Cohance's investor presentation; Cohance H1 was muted with key CDMO orders moving to H2, bullish on full year growth for Cohance both API+ and the CDMO business..
 - **CDMO + ADC Segment:** Expected to grow YoY in FY25, with shipment schedules largely towards H2.; One new innovator customer onboarded in Q2.
 - **API++:** Demand green shoots visible; delivered strong growth of 8% YoY in H1; On growth path already, expected to sustain the growth momentum.

No Change in Outlook: We reiterate our growth outlook, continue to expect growth in 2HFY25, with YoY growth at combined platform level in FY25 and further growth acceleration from FY26 onwards. We reiterate our aim to double combined business over next 5 years; M&A to act as growth accelerator.

Merger Update : Shareholder meeting to be convened on November 28, 2024.



Q2 and H1FY25 Operating and Financial Performance

Q2 and H1FY25 Earnings – Pharma CDMO leads the growth



Q2FY25 Performance:

- **Revenue growth of 12% is driven by Pharma CDMO business and Sapala acquisition.** The nature of our business remains lumpy hence quarter on quarter basis comparison is not advisable.
- **Q2FY25 Pharma CDMO posted a growth of 40% YoY**
 - Pharma CDMO growth is attributable to our strategic focus on BD efforts and commercial supplies.
 - Gross margins were at 79.8%
 - Adjusted EBITDA margins were at 43.3%
 - Free cash flow of Rs 1.10bn

H1FY25 updates:

- In H1, we have spent Rs 694mn on capex largely towards our R&D lab at Genome valley and Suryapet plant.
- Our Formulation plant at Casper (WOS) was audited by USFDA and we have received 2 procedural observations, received EIR with VAI status.
- We have recently been honored with the first company from India to be awarded PSCI supplier partner status.
- Received ISO 22301 (Business continuity) and ISO 50001 (Energy Management) certifications from DNV

Outlook:

- We continue to anticipate growth in FY25 at combined platform level

Q2 FY25 Consolidated Financial Highlights

12%

Revenue from operations (YoY), incl Sapala Rs 93mn

INR 2.6 bn

Total Revenue

43.3%

EBITDA% excl. one time

41%

Revenue Excl. Spec Chem (YoY)

INR 1.1bn*

Adjusted EBITDA

34.1%

Adjusted PAT %

40%

Pharma CDMO (YoY)


INR 878 Mn*

Adjusted Profit after Tax

*Incl. one-time adjustments of INR 52Mn and Op. forex gain of INR 23Mn.

Segmental Revenue Q2 FY25

FDC & Others
21%



Pharma CDMO
79%

Q2 FY25 Consolidated Financial results

INR Million

Particulars	Q2FY25	Q2FY24	Q1FY25	YoY		QoQ
				(in. Sapla)	(Ex. Sapla)	
Revenue from Operations	2,577	2,311	2,307	11.5%	7.5%	11.7%
Material costs / COGS	(521)	(576)	(636)			
Material Margin	2,057	1,735	1,671	18.6%	6.6%	23.1%
Material Margin %	79.8%	75.1%	72.4%			
Manufacturing Expenses	(312)	(316)	(271)			
Employee Cost	(519)	(308)	(453)			
Administrative Expenses	(153)	(102)	(127)			
S&D Expenses	(33)	(22)	(20)			
Total Expenses	1,016	748	872			
FX MTM gain	23	42	19			
EBIDTA (Reported)	1,063	1,028	818	3.4%	1.3%	30.0%
EBIDTA (Reported) %	41.3%	44.5%	35.5%			
Onetime expenses	52	0	56			
EBIDTA (Adjusted)	1,115	1,028	874	8.5%	6.4%	27.6%
EBIDTA (Adjusted) %	43.3%	44.5%	37.9%			
Depreciation & Amortization	(144)	(119)	(134)			
Finance costs	(17)	(11)	(16)			
Other income	118	157	163			
PBT (Adjusted)	1,073	1,054	887	-0.7%	0.2%	18.1%
Tax(Adjusted)	(194)	(258)	(237)			
PAT (Adjusted)	878	796	649	8.0%	8.8%	32.3%
PAT Margin	34.1%	34.4%	28.1%			
PAT (Reported)	820	796	608	3.1%	4.0%	35.0%
PAT Margin	31.8%	34.4%	26.3%			

- Q2FY25 reported 12% YoY growth supported by Pharma CDMO and Sapala consolidation.
- Excluding Sapala the growth was 7% YoY. We consolidated Sapala from 11th July onwards, revenue of Rs 93mn.
- Gross margins expanded 473 bps YoY, driven by the business mix and Sapala addition and Adjusted EEBITDA margins at 43.3%, reflect continued efforts and focus on operational efficiencies bolster by business mix.

Note: 1 Adjusted EBITDA includes one-time adjustments – of Rs 56mn in Q1FY25 and Rs 52mn in Q2FY25 primarily driven by ESOP charges, merger cost and acquisition expenses.

H1 FY25 Consolidated Financial results

INR Million

Particulars	H1FY25	H1FY24	YoY	
			(in. Sapla)	(Ex. Sapla)
Revenue from Operations	4,884	5,786	(15.6)%	(17.2)%
Material costs / COGS	(1,157)	(1,589)		
Material Margin	3,727	4,197	(11.2)%	(34.1)%
Material Margin %	76.3%	72.5%		
Manufacturing Expenses	(583)	(640)		
Employee Cost	(972)	(615)		
Administrative Expenses	(280)	(234)		
S&D Expenses	(53)	(45)		
Total Expenses	1,888	1,533		
FX MTM gain	42	52		
EBIDTA (Reported)	1,881	2,716	(30.7)%	(31.5)%
EBIDTA (Reported) %	38.5%	46.9%		
Onetime expenses	107	-		
EBIDTA (Adjusted)	1,989	2,716	(26.8)%	(27.6)%
EBIDTA (Adjusted) %	40.7%	46.9%		
Depreciation & Amortization	(278)	(246)		
Finance costs	(33)	(30)		
Other income	281	253		
PBT (Adjusted)	1,959	2,694	(28.2)%	(27.9)%
Tax(Adjusted)	432	692		
PAT (Adjusted)	1,527	2,002	(24.6)%	(24.3)%
PAT Margin	31.3%	34.6%		
PAT (Reported)	1,428	2,002	(28.7)%	(28.3)%
PAT Margin	29.2%	34.6%		

Note: 1 Adjusted EBITDA includes one-time adjustments – in H1 FY25 ESOP Rs.89mn & Merger expenses Rs.18mn.

- Gross margins expanded by 378 bps to 76.3%. Adjusted EBITDA margins stood at 40.7% with Adjusted EBITDA of Rs 1.99bn.
- The one- time expenses of Rs 107 mn was largely on account of ESOPs, acquisition and merger costs.

INR Million

Balance Sheet Highlights	
As on 30th September 2024	
Shareholders' funds	19,698
NCI- Sapala	501
Net Fixed assets	9,617
Other net assets ¹	4,060
Net cash/(debt) ²	6,521
Total Use of Funds	20,199

1) Other assets calculated as Inventories + Trade receivables + Non-current investments + Current tax assets + Other assets less Trade payables + deferred tax liabilities + Other liabilities at the end of the year. 2) Net cash/(debt) calculated as the Cash & cash equivalents (Cash and bank balances + current investments) less Total debt (Short-term and Long-term borrowings) at the end of the period.


Q2FY25 Business performance overview

Q2FY25 Consolidated Financials


Operational Revenue (INR Million)



Adjusted EBITDA (INR Million) — Margin (%)



Adjusted PAT (INR Million) — Margin (%)




Pharma CDMO incl Sapala (INR Million)




Pharma CDMO posted 40% YoY growth in Q2

Spec Chem (INR Million)



Due to the nature of the CDMO business, Quarterly comparisons are not ideal

Formulations & Other Services (INR Million)




Note: 1) Adjusted EBITDA includes one-time adjustments of INR 52Mn in Q2FY25, comprising largely an ESOP charge
2) Segment revenue 's are Restated.


H1FY25 Business performance overview

H1FY25 Consolidated Financials


Operational Revenue (INR Million)




Adjusted EBITDA (INR Million) — Margin (%)



Adjusted PAT (INR Million) — Margin (%)




Pharma CDMO incl Sapala (INR Million)



Spec Chem (INR Million)



Formulations & Other Services (INR Million)



Due to the nature of the CDMO business, Annual trends should be considered

Note: 1) Adjusted EBITDA includes one-time adjustments of INR 107Mn in H1FY25, comprising largely an ESOP charge
 2) Segment revenue 's are Restated.



Combined Business: Proforma Metrics H1 FY25



Proforma Merged Entity

HI FY25 INR Mn		+		=	Merged Company
Revenue	4,884		6,043		10,927
Adjusted EBITDA	1,989		1,537		3,526
Adjusted EBITDA margin %	40.7%		25.4%		32.3%
Adjusted PAT	1,527		787		2,314
Adjusted PAT margin %	31.3%		13.0%		21.2%
RoCE	23.6%		22.0%		22.7%
RoE	14.5%		19.7%		16.6%
(Net Debt) / Net Cash to Adj. EBITDAx	1.8X		(0.8)X		0.4X

Note: In Q1FY25- Cohance EBITDA includes adjustments for one-time costs of Rs 25mn; Suven EBITDA includes one-time adjustments of Rs 55.7mn
Source: Cohance LifeSciences Website published Investor Presentation

Proforma Merged Entity – Combined business mix

H1 FY25


**Sales Mix
(1HFY25)**

**Manufacturing
Facilities
(Regulatory
approved)**

R&D Centers

Capacity

**SUVEN
PHARMA**




5 (1)

2

~1,400 kL



**cohance
lifesciences**




7 (5)

4

~1,250 kL



Merged Company



12 (6)

6

~2,650 kL



Combined Business: Key segment wise strategy



Small Molecules, ADCs, Oligonucleotides and Peptides constitute ~52% of New Drug Additions to the Global Preclinical and Clinical Pipeline in 2024¹

Pharma CDMO

Small Molecules

- Intermediate Supply for 12 Commercial Patented molecules
- **7 molecules in Phase-3** translating into 12 intermediates
- **Big Pharma** contributes to >80% of business; growing customer base

*ADC

- Payload and Payload intermediate supply for two commercial ADCs
- Global leadership in one of payloads with active expansion to other payload families.
- Ongoing engagement with multiple customers in ADC clinical trials

Oligonucleotides

- Amongst few CDMOs globally specialized in Oligonucleotide and mRNA building blocks
- Extensive depth and width of capabilities in the high growth Nucleic Acid Segment supplying to various drugs in Clinical Trials
- Strong expertise in Modified Nucleosides and Amidites

Specialty Chemical incl Ag Chem (Now SBU)

Agro Chem

- Macro effect has bottomed out and we're expecting the business to stabilize and grow from here on. We have started seeing green shoots from our concerted BD efforts in this segment which suggest early signs of recovery
- Dedicated site for AgChem (Vizag), Space for future expansion.

*Other Specialty Chemicals

- Relationships with innovators in Cosmetics, Electronic Chemicals, Photochromic Lens and Energy Industries
- Successfully delivered innovator projects from gram to multi kilo scale
- Amongst India's leading manufacturers of high purity electronic chemicals; highly backward integrated

API ++

*API

- Downcycle in API++ is behind us – reported 8% growth in H1 with healthy order book.
- Focused portfolio and market leadership in low-mid volume, specialty APIs with low competitive intensity.
- Ongoing augmentation of new product pipeline planned to add 7+ new products in FY25.
- Wide network of capacities across platform with global regulatory accreditations.
- Built deep cost position through backward integration.
- Top 3 player in 8 out of 10 top molecules in the API portfolio.
- Offering end to end vertically integrated solutions including pellets and formulations.

Suven will build on its current strengths and invest in value adding capabilities for the future

Operations Strengths

>90%

OTIF (Commercial products) with **high quality** and plant uptime



Large Manufacturing Network and Available Capacities: 12 manufacturing (including 6 US FDA/EDQM audited sites) across platform



Best in class HSE standards & IP Protection



Wide and Differentiated Chemistry capabilities coupled with technology platforms like **ADC and Oligonucleotides**

Commercial Strengths



Global clientele of 50+ customers (including 14 of the top 20 Pharma Companies)



Established track-record of delivery of 1000+ projects



Diversified Customer Base: Big Pharma, Mid Pharma, Bio-techs, CDMOs, Specialty Chemicals, Generics



Presence across lifecycle of molecule: from discovery/preclinical to commercial with customized product offerings

Suven: Pharma CDMO – Small molecules

- **Phase III pipeline moving with higher conversions**

- Overall active pipeline of 100+ projects across Phase I – III
- We have 12 commercial Pharma molecules


- **Phase III pipeline**

- Our Phase three pipeline stands with 7 molecules with 12 intermediates
- Phase-III Readout positive for one of the products
- We have added one new Phase 3 molecule

- **Highest streak of RFQs inflow persists; Higher mix of laterals, RFQs from new customers and category expansion**

- Our 1H recorded 2.2x RFQs Vs previous year
- **Product mix:** Contribution from Late-Stage and Mid Stage RFQs has been growing in our pipeline; positions Suven favourably as a strategic partner on developments of laterals
- **Product type mix:** incremental contribution from new RFQs in H1FY25 contributed by Technology Projects like ADCs, Peptides, Oligonucleotide Fragments
- **Customer mix:** we have received some new RFQs from Biotech companies; Share of new customers has increased highlighting our strategic focus on R&D engagement and on broadening customer base

Suven's Phase III pipeline




RFQs Inflow



Favorable Industry Macros leading to growth in Small Molecule Pipeline

Small Molecule Pipeline continues to grow on the back of Oncology; Biologics as a % of Pipeline has been stable around 41-45%


Active Clinical Pipeline by Year



- The current size of the clinical pipeline has grown to 22,937 projects.
- Small Molecules is 52% of the current pipeline, Biologics 44% and Others (including Natural Substances) is 4%
- By far the largest chunk of drugs fall into the oncology bucket. Overall, Oncology is roughly 44% of the pipeline and growing. 51% of the Oncology Active Pipeline is small molecules

Small molecules: Increasing proportion of US FDA approvals

US FDA Approvals lean towards small molecules: ~70% of FDA Approvals 2023 and 9M 2024 are small molecules



Record Number of Approvals in 2023: 55 novel drugs were approved in 2023. This was the second-highest number of approvals in the last 10 years, after the 59 approved in 2018. Other notable statistics include:

- 36% of the approvals were considered first-in-class by the FDA
- 51% received Orphan Drug Designation for treating rare indications
- 45% were granted Fast Track Designation
- 16% were designated Breakthrough Therapies (including 2 small molecules)
- 16% were granted Accelerated Approval
- 84% received approval on their first review cycle

The positive trend continues in 2024: In 9M-2024, 34 novel drugs were approved by FDA, of which 24 were small molecules (71%)

Cohance CDMO: ADC Platform on track to deliver growth



ADC pipeline – progressing well

- Two commercial product continue to grow strong with the therapy expansion and market registrations.
- We have received RFQs from a large Pharma customer for an ADC product; under evaluation
- New orders received from newly onboarded customers, tracking well.

Leverage proprietary ADC platform capabilities to expand designer and adjacent payloads portfolio; complimentary to the portfolio

- R&D pipeline of new designer payloads and adjacent payloads in advanced stage of development.
- Broden's our payload offering; higher access to wider set of ADC customers

Several clinical developmental programs are ongoing

- Several RFQs in ADC payload for innovator clinical programs ongoing
- One molecule in early phase III, tracking well.

Cohance CDMO Order book – Shipment schedule skewed towards 2H

- Cohance H1 was muted with key orders scheduled for H2, bullish on full year growth of the CDMO business.

Non-ADC: CDMO – approved, to contribute growth in mid-long term


- Non-ADC **Phase III molecule, approved by USFDA** and will contribute towards near-mid-term growth.

Controlled Substance

- Extensive expertise and global leadership in regulated controlled substance products;
- Fully backward-integrated with a diverse portfolio of high-purity APIs;
- leverage capabilities to capture synthetic cannabinoid space.

Growing numbers of ADC candidates entering clinical trials

ADC entering CTs in each year*



*Source: Industry/Market data

ADC payloads – breakthrough chemistry ability

Cohance is the global pioneer in developing fully synthetic route for **camptothecin** based ADC payload platform; large-scale production

Cohance's **proprietary technology** allow to produce payload with **significantly higher level of purity**. The core capability allows Cohance the ability to develop all derivatives of payload family

Cohance has **organically developed** an adjacent payload platform. Ongoing validation by customers.


Both the platforms together cover **70%** of the ongoing clinical ADC pipeline

Technology Platform


Industry data projects ADC market to grow at a CAGR of 15-20% over coming 5 years.

ADC Segment market opportunity :

- **ADC payload:** The market for ADC payloads is projected to experience a CAGR of 12-15% over the next decade.
- **Linker Capabilities:** Planning to add Linker capability., another healthy growth segment.



Amongst the few CDMOs globally, supplying complex building blocks for Oligonucleotides




Nucleic acid & Oligo building blocks have an increasing R&D focus on Therapeutics and Drug development; Diagnostics & Biotechnology and Synthetic Biology

Market expected to grow strongly on the back of

- Increasing utilization of synthesized oligonucleotides in molecular diagnostics and clinical applications
- Increased investment in pharmaceutical and biotechnology companies

Oligonucleotide Synthesis Market (USD BN)



*Source: Industry/Market data

Oligonucleotides – Sapala acquisition consolidated

- We have consolidated the Sapala business from 11th July onwards in Q2FY25.
- Our commitment to expanding oligonucleotide business is clear, with investments in Phase 1 of cGMP facility underway.
- This investment enhances our capacity and broadens our service capabilities around the existing and upcoming R&D pipeline build-up.

Our platform with focus on Specialized building blocks

- Oligo tech platform - focused on building blocks incl Phosphoramidites & Nucleosides, drug delivery compounds (including GalNAc), Pseudouridine, amongst others
- Demonstrated ability in complex Carbohydrate and Nucleoside synthesis (15+ steps).
- Majority of the products are backward integrated
- **Diversified customer base with a strong Japan presence**
- Innovator Pharma, CDMOs & diagnostic cos. form our current customer base.
- Strong legacy in Japan; potential to leverage for Japan expansion

Pipeline update

- One product in the pipeline has received orphan drug status and is progressing on track.

Manufacturing and Operations

- 250+ employees. 100+member R&D team (including 20+ PhDs)
- R&D Lab and pilot manufacturing - with 17 fully equipped labs

Suven: Agri Chem recovery from H2

Cohance: Spec Chem niche capabilities

Suven's Spec/Agchem:

- We are seeing green shoots from our concerted BD efforts in this segment which suggest early signs of recovery.
- As we continue to build strategic partnerships, we're seeing new product discussions and fresh RFQs including from potential new customers.
- Development and Commercial mfg. with focus on intermediates and AIs
- Flexible capacity - Dedicated site for AgChem (Vizag), Space for future expansion, Kilo / Pilot scale facility available
- Improved processes, introducing EHS Best Practices

Cohance : Spec Chem

- Relationships with Originators in Cosmetics, Electronic Chemicals, Photochromic Lens and Energy Industries
- Successfully delivered innovator projects from gram to multi kilo scale
- Amongst India's leading manufacturers of high purity electronic chemicals;
- Highly backward integrated



Cohance: API ++ on growth path

Cohance API++ reported 8% YoY growth in H1 with healthy order book


What will accelerate the base growth:

- Portfolio is unique and can drive sustained growth
 - Business model focus is on small-mid volume APIs. These products segments have less concentration risk and limited pricing pressure.
 - Focus on expanding market share on the back of deep cost position backed by backward integration
 - Continue to be amongst the Top 3 players for most top molecules (8/10)
 - Capabilities to handle a drug end-to-end throughout its lifecycle
- Higher product validations over 18-24 months; well supported by our BD efforts; target to add 7+ new products in FY25
- **Outlook:** Back on a growth path, the growth momentum expected to sustain, backed by BD efforts, new product launches and market demand recovery.

Source: Cohance investor presentation

\$101+ Bn Total Addressable Market

Sustained growth



Small molecules continue to be a significantly large proportion of Merchant API market revenues

*Source: Industry/Market data



Strategic Blueprint

Aspiration

Be Most admired CDMO, known for technology, delivery, quality and innovation

Pharma CDMO

- Rising RFQs and lateral pipeline – both existing and new customers
- Moving up the value chain – increasing Phase III presence

ADC and Oligonucleotides

- Partnering with large innovators
- Adding organically new ADC platform
- Increasing contribution from product expansion on the existing platform base
- Expertise in Modified Nucleosides and Amidites

Spec Chem CDMO:

- Shaping strong Business development and Commercial capabilities
- Expanding number of RFQs – thrust on increasing contribution from Top 5 players

API++

- Unique portfolio focused on small and mid volume APIs
- Higher product validations, expanding market share

Governance

Organisation

Infrastructure


Capabilities: Supporting growth initiatives

Continuous improvement



ESG

We have set multi-dimensional ESG goals for the next 5 years





Update on Amalgamation of Suven Pharmaceuticals with Cohance Lifesciences





Merger – Approval update

- Received the approvals from the Stock Exchanges and SEBI
- NCLT has ordered to convene shareholders' meeting; To be held on Thursday, November 28, 2024
- Other regulatory approvals, if any to follow





Financial Performance Q2 & H1FY25



Suven P&L – Adjusted EBITDA margins at 41%



INR million										CAGR		YoY	
Consolidated P&L Snapshot	FY20	FY21	FY22	FY23	FY24	Q2FY24	Q2 FY25	H1FY24	H1 FY25	FY20-FY24	Q2	H1	
Revenue	8,338	10,097	13,202	13,403	10,514	2,311	2,577	5,786	4,884	6.0%	11.5%	(15.6)%	
COGS	(2,292)	(3,019)	(3,991)	(4,091)	(3,150)	(576)	(521)	(1,589)	(1,157)				
Material Margin	6,046	7,078	9,211	9,312	7,363	1,735	2,057	4,197	3,727	5.5%	18.6%	(11.2)%	
<i>Material Margin%</i>	72.5%	70.1%	69.8%	69.5%	70.0%	75.1%	79.8%	72.5%	76.3%				
Manufacturing Expenses	(1,038)	(1,338)	(1,732)	(1,763)	(1,224)	(316)	(312)	(640)	(583)				
Employee cost	(651)	(762)	(1,005)	(1,105)	(1,359)	(308)	(519)	(615)	(972)				
Other expenses	(540)	(573)	(680)	(702)	(722)	(124)	(188)	(279)	(333)				
EBITDA (pre Fx)	3,816	4,405	5,794	5,742	4,058	986	1,040	2,664	1,839	2.8%	5.5%	(31.0)%	
<i>EBITDA%</i>	45.8%	43.6%	43.9%	42.8%	38.6%	42.7%	40.4%	46.0%	37.7%				
Operating Forex gain / (loss)	50	115	138	268	81	42	23	52	42				
Onetime expenses	-	-	-	(134)	211	-	52	-	107				
Adjusted EBITDA (post Fx)	3,866	4,520	5,932	5,876	4,350	1,028	1,115	2,716	1,989	3.0%	8.5%	(26.8)%	
<i>EBITDA%</i>	46.4%	44.8%	44.9%	43.8%	41.4%	44.5%	43.3%	46.9%	40.7%				
Depreciation & Amortization	(235)	(316)	(391)	(480)	(502)	(119)	(144)	(246)	(278)				
Finance costs	(199)	(91)	(62)	(128)	(75)	(11)	(17)	(30)	(33)				
Other income	131	27	123	195	538	157	118	253	281				
Adjusted PBT	3,563	4,139	5,603	5,463	4,312	1,054	1,073	2,694	1,959	4.9%	1.8%	(27.3)%	
Tax	(875)	(1,053)	(2,138)	(1,451)	(1,118)	(258)	(194)	(692)	(432)				
Adjusted PAT	2,688	3,086	3,465	4,013	3,194	796	878	2,002	1,527	4.4%	10.3%	(23.7)%	
<i>PAT%</i>	32.2%	30.6%	26.2%	29.9%	30.4%	34.4%	34.1%	34.6%	31.3%				

Revenue growth in 1H muted given the order shipments schedule skewed towards H2.

The Pharma CDMO segment is expected to deliver growth in FY25, with shipment schedules largely towards 2H.

Gross margins improved by 157 bps YoY, driven by the business mix.

Adjusted EBITDA margins were 40.7%, reflecting our current investments aimed at steering Suven towards the next growth orbit.

Our PAT margins stood at 31.3% despite a revenue softness.

Suven Balance Sheet – Healthy cash rich B/s

INR million

Consolidated Balance Sheet Snapshot	FY20	FY21	FY22	FY23	FY24	H1 FY24	H1 FY25
Property, plant and equipment (PPE)	3,531	4,371	5,306	5,842	5,672	5,717	6,136
Right of use asset (RoU)	9	17	14	169	406	172	454
Capital work-in-progress	1,016	961	300	1,651	1,790	1,723	2,408
Intangible Assets	29	26	22	622	619	620	618
Fixed Assets	4,584	5,375	5,642	8,284	8,487	8,233	9,617
Inventories	1,749	2,011	2,834	3,128	2,312	2,715	2,155
Trade receivables	1,172	1,024	2,364	1,109	1,337	1,369	1,840
Trade payables	(711)	(829)	(1,059)	(701)	(424)	(426)	(653)
Core Net Working Capital (Core NWC)	2,210	2,205	4,139	3,537	3,225	3,658	3,342
Other net current assets	196	399	424	763	480	264	236
Other net non current assets	2,863	3,339	738	591	457	554	483
Borrowings	(1,853)	(1,412)	(956)	(692)	(386)	(491)	(91)
Cash and Cash equivalents (including liquid investments)	447	1,902	5,285	4,869	8,244	7,137	6,612
Net (debt) / cash	(1,405)	490	4,330	4,178	7,858	6,645	6,521
Net assets	8,448	11,808	15,272	17,352	20,507	19,354	20,199
Shareholder's funds	8,448	11,808	15,272	17,352	20,507	19,354	19,698
Non Controlling interests- Sapala							501

H1FY25 reflects Sapala consolidation

- Working capital under control despite Ag Chem de-stocking cycle.
- Free Cash generation in H1FY25 was Rs 1.1bn.
- Cash and bank balance of Rs 6.56bn, excludes other bank balances.

Suven – Key Ratios

Key Ratios	FY20	FY21	FY22	FY23	FY24	HI FY24	HI FY25	Basis
Net Working Capital (as days of sales)	97	80	114	96	112	115	125	Core NWC / Revenue * 365
PPE (as % of sales)	42.3%	43.3%	40.2%	43.6%	54.0%	54.4%	63.8%	Closing PPE / Revenue
Capex spend during the year (INR M)	1,029	1,108	752	2,857	518	268	694	
Capex spend (as % of sales)	12.3%	11.0%	5.7%	21.3%	4.9%	4.6%	14.2%	Capex spend / Revenue
(Net Debt)/ Net Cash to adjusted EBITDA (x times)	-0.4x	0.1x	0.7x	0.7x	1.8x	1.5x	1.8x	(Net Debt) or Net Cash/ Adjusted EBITDA
Adjusted EBIT (INR M)	3,631	4,203	5,541	5,396	3,848	3,848	2,654	Adjusted EBITDA - Depreciation and Amortization
Avg Capital employed (INR M)	6,655	7,242	8,739	10,586	11,070	11,168	11,247	Avg of Opening and Closing Capital employed (excluding Goodwill, Non-current investments and Cash & CE)
ROCE (%)	54.6%	58.0%	63.4%	51.0%	34.8%	34.5%	23.6%	Adjusted EBIT / Avg. Capital employed
Avg Shareholder's funds (INR M)	5,638	6,785	11,148	14,840	17,088	16,579	18,186	Avg of Opening and closing shareholder's funds (excluding Goodwill and Non-current investments)
ROE (%)	47.7%	45.5%	31.1%	27.0%	18.7%	19.3%	14.7%	Adjusted PAT / Avg Shareholder's funds

Note:

- 1) Key ratios computed on LTM basis for HIFY25
- 2) ROCE and ROE in HIFY25 reflects Sapala consolidation

Cohance Proforma P&L – Snapshot

INR million

Proforma P&L Snapshot	FY19	FY20	FY21	FY22	FY23	FY24	Q2FY24	Q2FY25	H1FY24	H1FY25	YoY		
											CAGR FY19-FY24	Q2	H1
Revenue	7,272	8,631	10,043	12,802	13,375	13,408	3,993	3,469	6,271	6,043	13.0%	(13.1)%	(3.6)%
COGS	(2,900)	(3,705)	(4,004)	(5,300)	(5,058)	(4,990)	(1,502)	(1,252)	(2,361)	(2,197)			
Material Margin	4,372	4,926	6,039	7,502	8,317	8,418	2,491	2,216	3,910	3,845	14.0%	(11.0)%	(1.7)%
<i>Material Margin%</i>	60.1%	57.1%	60.1%	58.6%	62.2%	62.8%	62.4%	63.9%	62.4%	63.6%			
Manufacturing Expenses	(1,058)	(955)	(1,123)	(1,277)	(1,480)	(1,282)	(320)	(323)	(666)	(589)			
Employee cost	(1,137)	(1,273)	(1,433)	(1,714)	(1,933)	(2,447)	(631)	(569)	(1,274)	(1,145)			
Other expenses	(584)	(657)	(693)	(879)	(839)	(1,279)	(212)	(315)	(468)	(644)			
EBITDA (pre Fx)	1,593	2,041	2,790	3,633	4,066	3,410	1,328	1,010	1,502	1,467	16.4%	(23.9)%	(2.3)%
<i>EBITDA%</i>							33.3%	29.1%	24.0%	24.3%			
Operating Forex gain / (loss)	19	174	146	69	147	21	11	18	13	21			
One-time Expenses(ESOP&Merger)						752	164	24	336	49			
Adjusted EBITDA (post Fx)	1,612	2,214	2,936	3,702	4,213	4,183	1,503	1,052	1,851	1,537	21.0%	(30.0)%	(17.0)%
<i>EBITDA%</i>	22.2%	25.7%	29.2%	28.9%	31.5%	31.2%	37.6%	30.3%	29.5%	25.4%			
Depreciation & Amortization	(479)	(444)	(469)	(509)	(522)	(637)	(144)	(181)	(280)	(332)			
Finance costs	(169)	(197)	(45)	(110)	(154)	(332)	(76)	(83)	(142)	(165)			
Other income	157	204	189	186	154	193	18	10	160	11			
Adjusted PBT	1,121	1,777	2,610	3,269	3,691	3,408	1,300	799	1,589	1,051	24.9%	(38.6)%	(33.9)%
Tax	(282)	(447)	(657)	(823)	(929)	(863)	(330)	(197)	(410)	(264)			
Adjusted PAT	839	1,330	1,953	2,446	2,762	2,544	970	602	1,179	787	24.9%	(38.0)%	(33.3)%
<i>PAT%</i>	11.5%	15.4%	19.4%	19.1%	20.6%	19.0%	24.3%	17.3%	18.8%	13.0%			
Accounting entries relating to merger of AI Pharmed and RA Chem													
Depreciation and amortization				(185)	(75)	(102)	(26)	(28)	(51)	(55)			
Tax impact of above				47	19	26	6	7	13	14			
PAT (post consol adjustments)				2,307	2,706	2,468	951	581	1,141	745			

- In 1H FY25 API++ segment posted growth of 8% YoY driven by healthy product launches and demand recovery.
- CDMO business expected grow in FY25, as orders schedules skewed towards H2
- Based on the current order book visibility, Cohance to post growth in FY25.
- EBITDA margins at 25%, driven by higher share of API++
- Cohance business is back on growth path we expect growth in FY25

Note: 1) Till FY23, proforma and adjusted financials of Cohance entities (RAC, ZCL and Avra) have been extracted from report issued by Deloitte Touche Tohmatsu India LLP. Adjusted P&L numbers are reported numbers adjusted out for one-time expenses and income; FY24 numbers as per audited financials of the merged entity (Cohance) 2) Manufacturing expenses include power and fuel, consumption of stores & spares, repairs & maintenance, EHS expenditure, etc. 3) Employee costs include on-payroll employee benefit expenses and contract employee expenses 4) Other expenses include Freight outward, Commission and brokerage, Legal and professional fees, Rates and taxes, Insurance, etc. 5) Adjusted EBITDA includes one-time adjustments of Rs.334mn incl. merger cost and ESOPs cost of Rs 418mn for FY24. One-time adjustments includes ESOP, merger & others Rs.49mn & 336mn for H1FY25 & H1FY24, respectively.

Cohance Proforma Balance Sheet – Snapshot

INR million

Proforma Balance Sheet Snapshot ¹	Mar19	Mar20	Mar21	Mar22	Mar23	Mar-24	HI FY24	HI FY25
Property, plant and equipment (PPE)	3,699	3,824	4,128	4,090	4,217	4,601	4,193	7,116
Right of use asset (RoU) ²	0	13	89	179	202	356	175	427
Capital work-in-progress	45	99	155	458	1,167	2,292	1,621	628
Intangible Assets ²	47	47	51	123	118	109	136	125
Fixed Assets	3,790	3,982	4,422	4,850	5,704	7,358	6,125	8,295
Inventories	1,674	1,894	2,551	3,266	3,641	3,674	3,649	3,766
Trade receivables	2,434	3,154	3,218	3,654	4,202	5,133	4,630	4,023
Trade payables	(852)	(1,305)	(1,716)	(1,670)	(2,141)	(1,994)	(1,749)	(2,130)
Core Net Working Capital (Core NWC)	3,256	3,743	4,052	5,250	5,703	6,813	6,531	5,659
Other net assets	(70)	(111)	(189)	(196)	218	65	1,328	669
Borrowings	(2,059)	(1,678)	(1,330)	(1,738)	(2,668)	(4,888)	(8,393)	(3,345)
Cash and Cash equivalents (including liquid investments)	3,323	3,470	3,918	4,111	974	1,197	1382	81
Net (debt) / cash	1,264	1,793	2,588	2,373	(1,694)	(3,692)	(7,011)	(3,264)
Net assets	8,239	9,406	10,874	12,277	9,931	10,545	6,972	11,359
Shareholder's funds	8,239	9,406	10,874	12,277	9,931	10,545	6,972	11,359
Accounting entries relating to merger of AI Pharmed and RA Chem								
Goodwill			5,800	5,800	5,800	5,800	5,800	5,800
Tangible assets			397	389	382	376	379	372
Intangible assets			803	624	556	454	505	402
Tax impact			(297)	(137)	(99)			
Other reconciling items			(21)	(20)	0			
Net assets (post consol adjustments)	8,239	9,406	17,556	18,932	16,569	17,174	13,656	17,933
Shareholder's funds	8,239	9,406	17,556	18,932	16,569	17,174	13,656	17,933

- Capex of Rs 1.06bn in HI. As we focus on increasing the flexibility towards backward integration, we have purchased a new facility from Avra Synthesis for Rs 415mn. And capitalized Ankleshwar block V with Rs1.38bn
- We continue to lower the debt, as cash diverted towards the debt repayment.
- As guided, borrowings to go down going forward.

Note:

1) Till FY23, proforma and adjusted financials of Cohance entities (RAC, ZCL and Avra) have been extracted from report issued by Deloitte Touche Tohmatsu India LLP. Adjusted P&L numbers are reported numbers adjusted out for one-time expenses and income; FY24 numbers as per audited financials of the merged entity (Cohance).

2) RoU and Intangible assets Includes RoU under development and intangibles under development respectively

Cohance Proforma – Key Ratios

Key Ratios	FY19	FY20	FY21	FY22	FY23	FY24	H1FY24	H1 FY25	Basis
Net Working Capital (as days of sales)	163	158	147	150	156	185	178	157	NWC / Revenue * 365
PPE (as % of sales)	50.9%	44.3%	41.1%	31.9%	31.5%	34.3%	31.3%	54.0%	PPE / Revenue
Capex spend during the year (INR M)	313	498	810	911	1,346	2,089	1,045	1,060	As per proforma cashflows
Capex spend (as % of sales)	4.3%	5.8%	8.1%	7.1%	10.1%	15.6%	7.8%	8.0%	Capex spend / Revenue
(Net Debt)/ Net Cash to adjusted EBITDA (x times)	0.8x	0.8x	0.9x	0.6x	-0.4x	-0.9x	-1.7x	-0.8x	Net Debt / Adjusted EBITDA
Adjusted EBIT (INR M)	1,133	1,771	2,466	3,193	3,691	3,545	3,545	3,180	Adjusted EBITDA - Depreciation and Amortization
Avg Capital employed (INR M)		7,294	7,949	9,095	10,764	12,931	12,804	14,430	Avg of opening and closing Capital employed (Net fixed assets + NWC + other net assets)
ROCE (%)		24.3%	31.0%	35.1%	34.3%	27.4%	27.7%	22.0%	Adjusted EBIT / Avg. Capital employed
Avg Shareholder's funds (INR M)		8,822	10,140	11,576	11,104	10,238	9,038	10,952	Avg of Opening and closing shareholder's funds
ROE (%)		15.1%	19.3%	21.1%	24.9%	24.9%	28.2%	19.6%	Adjusted PAT / Avg Shareholder's funds

ROCE for FY24 and H1FY25 reflects Group's higher growth capex yet to be optimally utilized

Note:

- 1) Till FY23, proforma and adjusted financials of Cohance entities (RAC, ZCL and Avra) have been extracted from report issued by Deloitte Touche Tohmatsu India LLP. Adjusted P&L numbers are reported numbers adjusted out for one-time expenses and income; FY24 numbers as per audited financials of the merged entity (Cohance).
- 2) RoU and Intangible assets Includes RoU under development and intangibles under development respectively

Proforma P&L Suven + Cohance Combined – Snapshot

INR million

Combined Proforma P&L Snapshot	FY20	FY21	FY22	FY23	FY24	Q2 FY24	Q2 FY25	HI FY24	HI FY25	CAGR	YoY	
										FY20-FY24	Q2	HI
Revenue	16,969	20,140	26,004	26,779	23,922	6,304	6,046	12,057	10,927	5.9%	(4.1)%	(9.4)%
COGS	(5,997)	(7,024)	(9,291)	(9,283)	(8,006)	(2,078)	(1,773)	(3,949)	(3,354)	6.9%	1.1%	(6.6)%
Material Margin	10,972	13,117	16,714	17,495	15,916	4,226	4,273	8,108	7,573			
<i>Material Margin%</i>	64.7%	65.1%	64.3%	65.3%	66.5%	67.0%	70.7%	67.2%	69.3%			
Manufacturing Expenses	(1,994)	(2,461)	(3,009)	(3,242)	(2,506)	(636)	(635)	(1,306)	(1,172)			
Employee cost	(1,924)	(2,195)	(2,719)	(3,038)	(3,771)	(939)	(1,087)	(1,889)	(2,117)			
Other expenses	(1,197)	(1,266)	(1,559)	(1,541)	(1,959)	(336)	(501)	(747)	(978)			
Adjusted EBITDA (pre Fx)	5,857	7,195	9,427	9,673	7,680	2,314	2,050	4,166	3,306	5.2%	(11.4)%	(20.6)%
Operating Forex gain / (loss)	224	261	208	415	102	53	41	65	63			
One time Expenses					752	164	76	336	157			
Adjusted EBITDA (post Fx)	6,080	7,455	9,635	10,089	8,534	2,531	2,167	4,567	3,526	6.9%	(14.4)%	(22.8)%
<i>EBITDA%</i>	35.8%	37.0%	37.1%	37.7%	35.7%	40.2%	35.8%	37.9%	32.3%			
Depreciation & Amortization	(679)	(786)	(900)	(1,002)	(1,139)	(263)	(325)	(526)	(610)			
Finance costs	(396)	(137)	(173)	(283)	(406)	(88)	(99)	(172)	(198)			
Other income	335	216	309	349	731	175	128	413	292			
Adjusted PBT	5,340	6,749	8,871	9,154	7,719	2,354	1,871	4,282	3,010	6.4%	(20.5)%	(29.7)%
Tax	(1,322)	(1,710)	(2,961)	(2,380)	(1,981)	(589)	(392)	(1,102)	(695)			
Adjusted PAT	4,018	5,039	5,911	6,775	5,738	1,766	1,480	3,181	2,314	6.6%	(16.2)%	(27.2)%
<i>PAT%</i>	23.7%	25.0%	22.7%	25.3%	24.0%	28.0%	24.5%	26.4%	21.2%			
Accounting entries relating to merger of AI Pharmed and RA Chem												
Depreciation and amortization			(185)	(75)	(102)	(26)	(53)	(51)	(81)			
Tax impact of above			47	19	26	6	13	13	20			
PAT (post consol adjustments)	4,018	5,039	5,772	6,718	5,662	1,747	1,440	3,143	2,254			

Revenue declined by 9% YoY, driven by order schedules skewed towards H2. Growth expected in 2H, FY25 to grow Vs FY24.

The gross and EBITDA margins were at 69.3% and 32.3%, respectively.

At a combined platform level, we anticipate growth in the second half of FY25, and further growth acceleration from FY26 onwards.

Note:

- 1) Till FY23, proforma and adjusted financials of Cohance entities (RAC, ZCL and Avra) have been extracted from report issued by Deloitte Touche Tohmatsu India LLP. Adjusted P&L numbers are reported numbers adjusted out for one-time expenses and income; FY24 numbers as per audited financials of the merged entity (Cohance).
- 2) RoU and Intangible assets includes RoU under development and intangibles under development respectively
- 3) Suven's EBITDA includes One-time adjustments includes ESOP, merger & others Rs.49mn & 336mn for HIFY25 & HIFY24, respectively. Cohance's Adjusted EBITDA includes one-time adjustments of Rs.334mn incl. merger cost and ESOPs cost of Rs 418mn for FY24.
- 4) Suven-Q2FY25 & HIFY25 numbers includes Sapala Consolidation

Proforma BS Suven + Cohance Combined – Snapshot

INR million

Combined Balance Sheet Snapshot ¹	FY20	FY21	FY22	FY23	FY24	H1 FY24	H1 FY25
Property, plant and equipment (PPE)	7,354	8,499	9,396	10,059	10,273	9,910	13,252
Right of use asset (RoU) ²	22	105	193	372	762	348	881
Capital work-in-progress	1,114	1,116	758	2,818	4,082	3,344	3,036
Intangible Assets ²	76	77	146	740	728	756	743
Fixed Assets	8,566	9,797	10,492	13,988	15,845	14,357	17,912
Inventories	3,643	4,562	6,100	6,769	5,986	6,364	5,921
Trade receivables	4,326	4,241	6,018	5,356	6,469	5,999	5,862
Trade payables	(2,016)	(2,546)	(2,729)	(2,940)	(2,418)	(2,175)	(2,782)
Core Net Working Capital (Core NWC)	5,953	6,257	9,389	9,185	10,038	10,189	9,000
Other net assets	2,947	3,549	965	1,626	1,002	2,146	1,388
Borrowings	(3,531)	(2,742)	(2,693)	(3,359)	(5,274)	(8,884)	(3,436)
Cash and Cash equivalents (including liquid investments)	3,918	5,820	9,396	5,843	9,440	8,519	6,693
Net (debt) / cash	387	3,078	6,703	2,484	4,167	(366)	3,257
Net assets	17,853	22,682	27,549	27,283	31,052	26,326	31,558
Shareholder's funds	17,853	22,682	27,549	27,282	31,052	26,326	31,057
Non Controlling Interests- Sapala							501

Proforma B/S numbers of the combined entity provides a Healthy net cash balance sheet.

Working capital with scope of improvement as we are back on growth path for Cohance business.

The indicative ROCE and ROE of the business is in H1FY25 at 22.7% and 16.6%, respectively.

Note:

- 1) Till FY23, proforma and adjusted financials of Cohance entities (RAC, ZCL and Avra) have been extracted from report issued by Deloitte Touche Tohmatsu India LLP. Adjusted P&L numbers are reported numbers adjusted out for one-time expenses and income; FY24 numbers as per audited financials of the merged entity (Cohance).
- 2) RoU and Intangible assets Includes RoU under development and intangibles under development respectively
- 3) Suven-Q2FY25 & H1FY25 numbers includes Sapala Consolidation

Suven + Cohance Combined Ratios

Key Ratios [#]	FY20	FY21	FY22	FY23	FY24	HI FY24	HI FY25	Basis
Net Working Capital (as days of sales)	128	113	132	125	153	155	144	NWC / Revenue * 365 days
PPE (as % of sales)	43.3%	42.2%	36.1%	37.6%	42.9%	41.4%	58.1%	PPE / Revenue
Capex spend during the year (INR M)	1,527	1,918	1,663	4,203	2,607	1,313	1,754	
Capex spend (as % of sales)	9.0%	9.5%	6.4%	15.7%	10.9%	7.7%	5.5%	Capex spend / Revenue
(Net Debt) / Net Cash to adjusted EBITDA (x times)	0.1x	0.4x	0.7x	0.2x	0.5x	0.0x	0.4x	Net Debt / Adjusted EBITDA
Adjusted EBIT (INR M)	5,402	6,670	8,735	9,087	7,394	7,394	5,834	Adjusted EBITDA - Depreciation and Amortization
Avg Capital employed (INR M)	13,949	15,192	17,833	21,350	24,001	23,972	25,676	Avg of opening and closing Capital employed (Net fixed assets + NWC + other net assets)
ROCE (%)	38.7%	43.9%	49.0%	42.6%	30.8%	30.8%	22.7%	Adjusted EBIT / Avg. Capital employed
Avg Shareholder's funds (INR M)	14,460	16,924	22,724	25,944	27,326	29,138	25,618	Avg of Opening and closing shareholder's funds
ROE (%)	27.8%	29.8%	26.0%	26.1%	21.0%	22.4%	16.6%	Adjusted PAT / Avg Shareholder's funds

calculated based on Proforma P&L and Balance Sheet of Suven + Cohance combined

Note:

- 1) Till FY23, proforma and adjusted financials of Cohance entities (RAC, ZCL and Avra) have been extracted from report issued by Deloitte Touche Tohmatsu India LLP. Adjusted P&L numbers are reported numbers adjusted out for one-time expenses and income; FY24 numbers as per audited financials of the merged entity (Cohance).
- 2) RoU and Intangible assets Includes RoU under development and intangibles under development respectively
- 3) Key ratios computed on Annualized basis for HIFY25 & HIFY24
- 4) Suven-Q2FY25 & HIFY25 numbers includes Sapala Consolidation



Annexure

Appendix – Adequate Capacity to serve current and future demand

Vizag, Andhra Pradesh, India

API's/Advanced Intermediate's/CMO

- 706 KL reactor volume
- 3KL to 12KL Reactors
- GL/SS (45No's)



Pashamylaram, Telangana, India

API & Formulation Facility


- 406 KL reaction volume
- 50L – 6000 L GL/SS (45)
- R&D



Suryapet, Telangana, India

Intermediate Facility

- 300 CM reactors (93)
- 665¹ KL GL/SS
- GMP Intermediates



Hyderabad Knowledge City, Hyderabad, India Corporate Office



Jeedimetla, Telangana, India

R&D–Pilot Plant

- Process Research
- Discovery R&D, Analytical R&D
- Killo lab, 30L CM Reactors (32)
- 27 KL GL/SS



Genome Valley, Hyderabad, India

R&D

- Synergy Square I, Genome Valley,
- Shamirpet, Hyderabad,
- Telangana – 500078



USA, New Jersey

Business Office

- Business Development
- Project Management
- Intellectual Property Management

COHANCE'S Specialized manufacturing capabilities

API Unit-1, Andhra Pradesh, India

- 120 reactors, > 520KI capacity
- USFDA (latest in 2019)
- EDQM (latest in 2023)
- Others: Korea-FDA, PMDA-Japan, COFEPRIS-Mexico, ANVISA-Brazil, MOH-Russia, CDSCO, WHO GMP



API Unit-2, Andhra Pradesh, India

- 46 reactors, >140KI capacity
- EDQM (latest in 2023)



API Unit-3, Gujrat, India

- 68 reactors, >420KI capacity
- USFDA (latest in 2023)
- EDQM (latest in 2017)
- Others: PMDA-Japan, COFEPRIS-Mexico, Korea-FDA, ANVISA-Brazil



FDF Unit-1, Telangana, India

- 1.8Bn OSDs and 350MT Pellets per annum
- USFDA (latest in 2019)
- EU GMP (latest in 2023)
- Others: MHRA, Health Canada, EU GMP, PMDA-Japan, MOH-Russia, WHO GMP, DCGI, Saudi-FDA, Taiwan-FDA



API Unit-4, , Telangana, India

- 60 reactors, >40KI capacity, Unit with Oncology facility
- USFDA (latest in 2019)
- EDQM (latest in 2024)
- Others: WHO GMP



API Unit-5, Andhra Pradesh, India

- 49 reactors, >130KI capacity
- GMP



FDF Unit-2, Telangana, India

- 480MT Pellets per annum
- WHO GMP

Contact Information



Cyndrella Carvalho, Head - Investor Relations,
Suven Pharmaceutical Ltd

Tel: +91 9823615656

Email: cyndrella.carvalho@suvenpharm.com

Gavin Desa / Rishab Barar
CDR - India

Tel: +91 98206 37649/ +91 77770 35061

Email: gavin@cdr-india.com / rishab@cdr-india.com



Thank You